Arcus Biosciences, Inc. (RCUS) — SEC Financial Statements & Analysis

Arcus Biosciences, Inc. (RCUS) is a pharmaceutical preparations company, incorporated in DE. Arcus Biosciences, Inc. trades on NYSE as: RCUS. Arcus Biosciences, Inc. (RCUS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Arcus Biosciences, Inc. carries a market cap of $3.89B, a P/E ratio of -8.45x, a P/B ratio of 8.38x, a P/S ratio of 33.23x, an enterprise value of $3.84B, and an EV/EBITDA multiple of -8.06x. On profitability, it posts an operating margin of -415.38%, a net margin of -393.16%, a Return on Equity (ROE) of -90.82%, a Return on Assets (ROA) of -46.02%, and a Return on Invested Capital (ROIC) of -118.45%. Per share, it reports EPS of $-3.65, diluted EPS of $-3.65, free cash flow per share of $-3.77, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -55.34% year-over-year, net income growth of 54.36% year-over-year, and EPS growth of 29.88% year-over-year. On the balance sheet, it maintains a current ratio of 3.82x, a quick ratio of 3.73x, working capital of $558.00M, a debt-to-equity ratio of 0.43x, a debt ratio of 0.21, an interest coverage ratio of -44.18x, free cash flow of $-475.00M (TTM), and net debt of $-49.00M. Figures sourced from SEC EDGAR.

Market Cap

$3.89B

P/E TTM

-8.45x

EPS TTM

$-3.65

P/B TTM

8.38x

ROE TTM

-90.82%

ROA TTM

-46.02%

Debt To Equity

0.43x

Free Cash Flow TTM

$-475.00M

Net Revenue TTM Growth 1Y

-55.34%

Data as of 2026-06-30 · Source: SEC EDGAR